Free Trial
NASDAQ:RNA

Avidity Biosciences (RNA) Stock Price, News & Analysis

Avidity Biosciences logo
$45.09
+0.27 (+0.60%)
(As of 11/5/2024 ET)

About Avidity Biosciences Stock (NASDAQ:RNA)

Key Stats

Today's Range
$43.39
$45.43
50-Day Range
$40.46
$50.45
52-Week Range
$5.15
$50.78
Volume
764,818 shs
Average Volume
1.31 million shs
Market Capitalization
$4.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.22
Consensus Rating
Buy

Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

RNA MarketRank™: 

Avidity Biosciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 677th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avidity Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Avidity Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.94) to ($3.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avidity Biosciences is -15.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avidity Biosciences is -15.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avidity Biosciences has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Avidity Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.55% of the outstanding shares of Avidity Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Avidity Biosciences has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avidity Biosciences has recently increased by 0.74%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Avidity Biosciences does not currently pay a dividend.

  • Dividend Growth

    Avidity Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.55% of the outstanding shares of Avidity Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Avidity Biosciences has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avidity Biosciences has recently increased by 0.74%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Avidity Biosciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Avidity Biosciences this week, compared to 5 articles on an average week.
  • Search Interest

    Only 5 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,995,842.00 in company stock.

  • Percentage Held by Insiders

    Only 3.68% of the stock of Avidity Biosciences is held by insiders.

  • Read more about Avidity Biosciences' insider trading history.
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Stock News Headlines

Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Avidity Biosciences price target raised to $65 from $60 at Chardan
See More Headlines

RNA Stock Analysis - Frequently Asked Questions

Avidity Biosciences' stock was trading at $9.05 at the beginning of the year. Since then, RNA shares have increased by 398.2% and is now trading at $45.09.
View the best growth stocks for 2024 here
.

Avidity Biosciences, Inc. (NASDAQ:RNA) issued its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.11. The biotechnology company earned $2.05 million during the quarter, compared to analyst estimates of $7.09 million. Avidity Biosciences had a negative net margin of 2,381.82% and a negative trailing twelve-month return on equity of 32.89%.

Avidity Biosciences (RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

Top institutional investors of Avidity Biosciences include Fiera Capital Corp (0.39%), Raymond James & Associates (0.14%), Hennion & Walsh Asset Management Inc. (0.07%) and State of New Jersey Common Pension Fund D (0.04%). Insiders that own company stock include Sarah Boyce, Michael F Maclean, Teresa Mccarthy, W Michael Flanagan, Arthur A Levin and Tamar Thompson.
View institutional ownership trends
.

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/09/2024
Today
11/05/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.22
High Stock Price Target
$96.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+40.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-212,220,000.00
Net Margins
-2,381.82%
Pretax Margin
-2,381.82%

Debt

Sales & Book Value

Annual Sales
$9.56 million
Book Value
$6.76 per share

Miscellaneous

Free Float
105,760,000
Market Cap
$4.95 billion
Optionable
Optionable
Beta
0.91

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:RNA) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners